
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
c-Fms/CSF-1R CRISPR Activation Plasmid (m) | sc-419839-ACT | 20 µg | $397.00 |
Csf1r encodes the receptor tyrosine kinase c-Fms/CSF-1R, a key regulator of monocyte–macrophage lineage commitment, survival, and functional polarization in mouse. Upon binding CSF-1 or IL-34, CSF-1R activates downstream PI3K–AKT, MAPK/ERK, and JAK/STAT signaling to coordinate proliferation, chemotaxis, and inflammatory gene programs. CSF-1R activity shapes tissue-resident macrophage homeostasis and osteoclast differentiation, influencing bone remodeling and developmental processes. Dysregulated Csf1r signaling and macrophage biology are widely implicated in neuroinflammation, tumor-associated myeloid cell function, and chronic inflammatory disease models.
c-Fms/CSF-1R CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Csf1r expression without altering the underlying DNA sequence.
c-Fms/CSF-1R CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Csf1r locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Csf1r transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous c-Fms/CSF-1R expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Csf1r locus and enabling the study of c-Fms/CSF-1R-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of c-Fms/CSF-1R pathway restoration in tumor cells with silenced or reduced Csf1r expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.